Thread

BREAKING: BioNTech mRNA Cancer “Vaccine” Trial TERMINATED Over Alarming Mortality Signal The independent Data Safety Monitoring Board flagged an overall-survival imbalance after cancer victims received an aggressive hyper-dosing regimen of up to 15 IV mRNA doses. BioNTech has NOT disclosed the direction of the mortality imbalance or the death counts in each arm. That data needs to be released immediately. The Phase 2 trial tested autogene cevumeran (BNT122) in patients with resected high-risk Stage II/III colorectal cancer who remained ctDNA-positive after surgery. As the vaccine cartel races to push mRNA technology into an ever-expanding list of diseases, this trial marks yet another MAJOR FAILURE of the platform—this time in cancer patients, where the stakes could not be higher. It’s time to END the unchecked expansion of mRNA technology and protect innocent civilians from further death and disability.